X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (30) 30
index medicus (29) 29
female (28) 28
oncology (19) 19
adult (17) 17
middle aged (17) 17
aged (15) 15
breast cancer (14) 14
breast neoplasms - drug therapy (13) 13
cancer (13) 13
chemotherapy (11) 11
male (11) 11
pharmacology & pharmacy (9) 9
antineoplastic agents - therapeutic use (8) 8
trastuzumab (8) 8
tumors (8) 8
breast neoplasms - pathology (7) 7
disease-free survival (7) 7
life sciences (7) 7
metastasis (7) 7
breast neoplasms - genetics (6) 6
cancer therapies (6) 6
medical prognosis (6) 6
mutation (6) 6
patients (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
brain neoplasms - genetics (5) 5
combination (5) 5
dna methylation (5) 5
endocrine therapy (5) 5
kaplan-meier estimate (5) 5
metastatic breast cancer (5) 5
temozolomide (5) 5
animals (4) 4
antigens (4) 4
antineoplastic agents - pharmacology (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
brain neoplasms - drug therapy (4) 4
breast neoplasms - metabolism (4) 4
care and treatment (4) 4
chromosome deletion (4) 4
drug resistance, neoplasm (4) 4
gene expression (4) 4
glioblastoma (4) 4
medicine & public health (4) 4
ovarian cancer (4) 4
phase-i (4) 4
proportional hazards models (4) 4
retrospective studies (4) 4
survival (4) 4
survival analysis (4) 4
therapy (4) 4
treatment outcome (4) 4
young adult (4) 4
1st-line treatment (3) 3
[sdv.can]life sciences [q-bio]/cancer (3) 3
abstracts (3) 3
aged, 80 and over (3) 3
antibodies, monoclonal, humanized - therapeutic use (3) 3
antimitotic agents (3) 3
antineoplastic agents (3) 3
antitumor-activity (3) 3
article (3) 3
biology (3) 3
biomarkers (3) 3
brain cancer (3) 3
brain neoplasms - mortality (3) 3
brain neoplasms - pathology (3) 3
brain neoplasms - radiotherapy (3) 3
clinical neurology (3) 3
clinical trials (3) 3
colorectal neoplasms - drug therapy (3) 3
dacarbazine - administration & dosage (3) 3
dacarbazine - analogs & derivatives (3) 3
dose-escalation (3) 3
epidermal growth factor (3) 3
genes (3) 3
glioblastoma - drug therapy (3) 3
glioblastoma - mortality (3) 3
her2 (3) 3
identification (3) 3
medicine (3) 3
mutations (3) 3
olaparib (3) 3
ovarian neoplasms - drug therapy (3) 3
phase-ii (3) 3
phase-ii trial (3) 3
piperazines - therapeutic use (3) 3
quality of life (3) 3
quality-of-life (3) 3
receptor, erbb-2 - antagonists & inhibitors (3) 3
receptor, erbb-2 - metabolism (3) 3
resistance (3) 3
trial (3) 3
validation (3) 3
womens health (3) 3
abemaciclib (2) 2
adjustment (2) 2
adjuvant temozolomide (2) 2
adults (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Weller, Michael and Butowski, Nicholas and Tran, David D and Recht, Lawrence and Recht, Lawrence D and Lim, Michael and Hirte, Hal and Ashby, Lynn and Mechtler, Laszlo and Goldlust, Samuel and Goldlust, Samuel A and Iwamoto, Fabio and Drappatz, Jan and O'Rourke, James and O'Rourke, Donald M and Wong, Mark and Hamilton, Mark G and Hamilton, Mark and Finocchiaro, Gaetano and Perry, James and Wick, Wolfgang and Green, Jennifer and He, Yi and Turner, Christopher D and Yellin, Michael J and Keler, Tibor and Davis, Thomas A and Stupp, Roger and Sampson, John H and Campian, Jian and Becker, Kevin and Barnett, Gene and Nicholas, Garth and Desjardins, Annick and Benkers, Tara and Wagle, Naveed and Groves, Morris and Kesari, Santosh and Horvath, Zsolt and Merrell, Ryan and Curry, Richard and Schuster, David and Mrugala, Maciej and Jensen, Randy and Trusheim, John and Lesser, Glenn and Belanger, Karl and Sloan, Andrew and Purow, Benjamin and Fink, Karen and Raizer, Jeffrey and Schulder, Michael and Nair, Suresh and Peak, Scott and Brandes, Alba and Mohile, Nimish and Landolfi, Joseph and Olson, Jon and Jennens, Ross and DeSouza, Paul and Robinson, Bridget and Crittenden, Marka and Shih, Kent and Flowers, Alexandra and Ong, Shirley and Connelly, Jennifer and Hadjipanayis, Costas and Giglio, Pierre and Mott, Frank and Mathieu, David and Lessard, Nathalie and Sepulveda, Sanchez Juan and Lövey, József and Wheeler, Helen and Inglis, Po-Ling and Hardie, Claire and Bota, Daniela and Lesniak, Maciej and Portnow, Jana and Frankel, Bruce and Junck, Larry and Thompson, Reid and Berk, Lawrence and McGhie, John and Macdonald, David and Saran, Frank and Soffietti, Riccardo and Blumenthal, Deborah and André de, Sá Barreto Costa Marcos and Nowak, Anna and Singhal, Nimit and Hottinger, Andreas and Schmid, Andrea and Srkalovic, Gordan and Baskin, David and Fadul, Camilo and Nabors, Louis and LaRocca, Renato and Villano, John and Paleologos, Nina and ... and ACT IV Trial Investigators and ACT IV trial investigators
The Lancet Oncology, ISSN 1470-2045, 10/2017, Volume 18, Issue 10, pp. 1373 - 1385
Rindopepimut (also known as CDX-110), a vaccine targeting the deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet... 
GLIOMAS | ONCOLOGY | RECURSIVE PARTITIONING ANALYSIS | GROWTH-FACTOR | RADIOTHERAPY | CANCER | PEPTIDE | ADJUVANT TEMOZOLOMIDE | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Brain Neoplasms - pathology | ErbB Receptors - genetics | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Dose-Response Relationship, Drug | Young Adult | Glioblastoma - genetics | Time Factors | Dacarbazine - analogs & derivatives | Adult | Female | Vaccines, Subunit - adverse effects | Brain Neoplasms - mortality | Dacarbazine - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cancer Vaccines - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Neoplasms - genetics | Cancer Vaccines - adverse effects | Treatment Outcome | Brain Neoplasms - drug therapy | Disease-Free Survival | Internationality | Vaccines, Subunit - administration & dosage | Glioblastoma - pathology | Survival Analysis | Aged | Temozolomide | Glioblastoma - drug therapy | Glioblastoma - mortality | Antimitotic agents | Clinical trials | Care and treatment | Product development | Antineoplastic agents | Glioblastoma multiforme | Analysis
Journal Article
Expert review of anticancer therapy, ISSN 1473-7140, 03/2019, pp. 1 - 11
Pertuzumab, a humanized monoclonal antibody that binds the human epidermal growth factor receptor 2 (HER2), inhibits the heterodimerization of HER2 with other... 
Journal Article
Drugs, ISSN 0012-6667, 9/2018, Volume 78, Issue 13, pp. 1353 - 1362
Deregulated cell division, resulting in aberrant cell proliferation, is one of the key hallmarks of cancer. Cyclin-dependent kinases (CDKs) play a central role... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | PALBOCICLIB | DEPENDENT KINASE 4/6 | R-ROSCOVITINE | PREDICTIVE BIOMARKER | GENE | ENDOCRINE THERAPY | PHARMACOLOGY & PHARMACY | CELL-CYCLE | TOXICOLOGY | ABEMACICLIB | ANTITUMOR-ACTIVITY | PHASE-I | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Humans | Drug Resistance, Neoplasm | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Breast Neoplasms - metabolism | Aminopyridines - therapeutic use | Female | Antineoplastic Agents - pharmacology | Purines - therapeutic use | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Purines - pharmacology | Cyclin-Dependent Kinase 6 - metabolism | Piperazines - therapeutic use | Cyclin-Dependent Kinase 4 - metabolism | Breast Neoplasms - drug therapy | Piperazines - pharmacology | Protein Kinase Inhibitors - therapeutic use | Aminopyridines - pharmacology | Progression-Free Survival | Benzimidazoles - pharmacology | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Cell proliferation | Deregulation | Phosphorylation | Toxicity | Clinical trials | Metastasis | Kinases | Cancer therapies | Phase transitions | Cyclin-dependent kinase 4 | Proteins | Cell growth | Epidermal growth factor | Cell cycle | Cyclin-dependent kinases | Cell division | Endocrine therapy | Breast cancer | FDA approval | Gene expression | Chemotherapy | Inhibitors | Medical prognosis | Biomarkers | Breast | Cancer | Tumors | Index Medicus
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 04/2013, Volume 73, Issue 8 Supplement, pp. 1189 - 1189
Journal Article
Expert Opinion on Drug Metabolism & Toxicology, ISSN 1742-5255, 02/2019, Volume 15, Issue 2, pp. 85 - 91
Journal Article
Expert Opinion on Pharmacotherapy, ISSN 1465-6566, 12/2017, Volume 18, Issue 18, pp. 2007 - 2016
Introduction: Breast cancer is the most frequent cancer in women. Despite a decline in breast cancer mortality, prognosis of advanced breast cancer remains... 
Breast cancer | chemotherapy | phosphatidylinositol-3-kinase | buparlisib | endocrine therapy | ADVANCED SOLID TUMORS | I PI3K INHIBITOR | NVP-BKM120 | KINASE INHIBITOR | BKM120 | DOSE-ESCALATION | PATHWAY | CLINICAL-TRIALS | GROWTH | PHARMACOLOGY & PHARMACY | PHASE-I | Index Medicus
Journal Article
Journal Article
Expert Opinion on Pharmacotherapy, ISSN 1465-6566, 09/2016, Volume 17, Issue 13, pp. 1817 - 1823
Journal Article
International Journal of Oncology, ISSN 1019-6439, 06/2012, Volume 40, Issue 6, pp. 2058 - 2062
Previous studies have identified mutations of the isocitrate dehydrogenase 1 (IDH1) gene in more than 70% of World Health Organization (WHO) grade 11 and III... 
Immunohistochemistry | Allele-specific PCR | Isocitrate dehydrogenase 1 | Sequencing | Oligodendrogliomas | oligodendrogliomas | ASSAY | ONCOLOGY | CODON 132 MUTATION | EUROPEAN ORGANIZATION | immunohistochemistry | SENSITIVE DETECTION | allele-specific PCR | isocitrate dehydrogenase 1 | sequencing
Journal Article
FRONTIERS IN GENETICS, ISSN 1664-8021, 09/2019, Volume 10
The acknowledgment that pollutants might influence the epigenome raises serious concerns regarding their long-term impact on the development of chronic... 
METHYLATION | SUBTYPES | epigenetic mark | FOLATE SUPPLEMENTATION LIMITS | breast cancer | ten-eleven translocation | BREAST-CANCER | DNA | hypomethylation | GROWTH | GENETICS & HEREDITY | DNA methylation | EXPRESSION | Glyphosate | Tumors | Life Sciences | Cancer
Journal Article
Molecular Therapy - Nucleic Acids, ISSN 2162-2531, 12/2018, Volume 13, pp. 642 - 650
In the last decade, microRNAs (miRs) have been described as biomarkers and therapeutic agents. Based on this finding, our aim here is to know if (1)... 
temozolomide | miRNA | GBM | PATHOGENESIS | MEDICINE, RESEARCH & EXPERIMENTAL | INHIBITION | MICRORNAS | TUMORS | TEMOZOLOMIDE | Prognosis | Cell survival | Brain cancer | Glioblastoma | MiRNA | Clinical trials | Gene expression | Experiments | Proteins | Medical prognosis | MicroRNAs | Biomarkers | Tumors | Apoptosis | Life Sciences | Cancer
Journal Article